X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (22820) 22820
Newsletter (98) 98
Magazine Article (16) 16
Book Chapter (15) 15
Reference (9) 9
Conference Proceeding (4) 4
Dissertation (4) 4
Publication (4) 4
Book / eBook (3) 3
Government Document (1) 1
Newspaper Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (12769) 12769
male (7857) 7857
urea - pharmacology (7044) 7044
urea (6688) 6688
humans (6242) 6242
rats (6032) 6032
female (4188) 4188
blood urea nitrogen (3686) 3686
pharmacology & pharmacy (3228) 3228
biochemistry & molecular biology (2681) 2681
mice (2630) 2630
urea - analogs & derivatives (2572) 2572
urea - metabolism (2378) 2378
creatinine - blood (2330) 2330
kinetics (1884) 1884
kidney - drug effects (1883) 1883
urea - blood (1824) 1824
time factors (1736) 1736
chemistry, medicinal (1572) 1572
dose-response relationship, drug (1550) 1550
rats, wistar (1483) 1483
adult (1470) 1470
analysis (1394) 1394
hydrogen-ion concentration (1381) 1381
oxidative stress (1294) 1294
proteins (1288) 1288
rats, sprague-dawley (1265) 1265
middle aged (1261) 1261
research (1228) 1228
liver - metabolism (1226) 1226
kidney - metabolism (1214) 1214
kidney - pathology (1197) 1197
toxicology (1140) 1140
urea - chemistry (1139) 1139
in vitro techniques (1136) 1136
liver - drug effects (1074) 1074
structure-activity relationship (1072) 1072
creatinine (988) 988
metabolism (983) 983
enzymes (978) 978
physiology (957) 957
liver (947) 947
expression (936) 936
physiological aspects (884) 884
kidneys (860) 860
disease models, animal (844) 844
temperature (844) 844
cattle (817) 817
aged (815) 815
toxicity (796) 796
rodents (792) 792
inflammation (789) 789
pharmacology (784) 784
antioxidants (783) 783
protein denaturation (781) 781
rabbits (771) 771
research article (768) 768
kidney (767) 767
models, molecular (760) 760
apoptosis (751) 751
protein folding (749) 749
cell biology (742) 742
dogs (703) 703
osmolar concentration (686) 686
rats, inbred strains (686) 686
protein conformation (674) 674
nephrotoxicity (666) 666
medicine, research & experimental (641) 641
cells (614) 614
body weight - drug effects (611) 611
inhibition (609) 609
circular dichroism (601) 601
glucose (599) 599
protein binding (599) 599
oxidative stress - drug effects (590) 590
blood (580) 580
cells, cultured (580) 580
protein (575) 575
cancer (572) 572
enzyme inhibitors - pharmacology (572) 572
thermodynamics (565) 565
molecular structure (564) 564
chemistry (559) 559
body weight (556) 556
binding sites (551) 551
immunology (551) 551
nitrogen - metabolism (547) 547
liver - enzymology (543) 543
rat (540) 540
urology & nephrology (539) 539
kidney diseases - chemically induced (536) 536
chemistry, organic (532) 532
health aspects (532) 532
molecular weight (529) 529
activation (526) 526
urea - urine (519) 519
biophysics (517) 517
agriculture, dairy & animal science (512) 512
chemistry, multidisciplinary (508) 508
in-vitro (505) 505
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (21471) 21471
German (539) 539
Japanese (504) 504
Russian (325) 325
French (195) 195
Italian (131) 131
Chinese (102) 102
Polish (52) 52
Spanish (47) 47
Ukrainian (24) 24
Czech (16) 16
Slovak (9) 9
Portuguese (8) 8
Romanian (7) 7
Dutch (6) 6
Bulgarian (5) 5
Hungarian (5) 5
Swedish (5) 5
Turkish (5) 5
Danish (4) 4
Korean (2) 2
Croatian (1) 1
Norwegian (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of neuroscience, ISSN 1529-2401, 2011, Volume 31, Issue 41, pp. 14600 - 14610
Orexin A and B are hypothalamic peptides known to modulate arousal, feeding, and reward via OX1 and OX2 receptors. Orexins are also antinociceptive in the... 
ENERGY HOMEOSTASIS | SYNAPTIC-TRANSMISSION | FEEDING-BEHAVIOR | PHOSPHOLIPASE-C | NEURONS | SPINAL-CORD | DIACYLGLYCEROL LIPASE | STRESS-INDUCED ANALGESIA | NEUROSCIENCES | HIPPOCAMPAL SYNAPSES | HYPOCRETIN OREXIN | Cannabinoid Receptor Modulators - pharmacology | Benzoxazoles - pharmacology | Electric Stimulation | Neural Pathways - drug effects | Rats, Wistar | Receptors, G-Protein-Coupled - metabolism | gamma-Aminobutyric Acid - metabolism | Periaqueductal Gray - drug effects | Male | Receptors, Neuropeptide - metabolism | Intracellular Signaling Peptides and Proteins - metabolism | Pain - metabolism | Neural Pathways - physiology | Lactones - pharmacology | Neural Inhibition - physiology | Biphenyl Compounds - pharmacology | Piperidines - pharmacology | Pain - drug therapy | Estrenes - pharmacology | Pyrrolidinones - pharmacology | Urea - analogs & derivatives | Endocannabinoids | Disease Models, Animal | Pyrazoles - pharmacology | Animals, Newborn | Orexins | Enzyme Inhibitors - pharmacology | Receptors, Neuropeptide - antagonists & inhibitors | Morpholines - pharmacology | Rats | Neuropeptides - metabolism | Pain Measurement - drug effects | Orexin Receptors | Pain - pathology | Arachidonic Acids - pharmacology | Naphthalenes - pharmacology | Calcium Channel Blockers | Glycerides - pharmacology | Patch-Clamp Techniques | Animals | Analysis of Variance | Benzoxazines - pharmacology | Receptors, G-Protein-Coupled - antagonists & inhibitors | Periaqueductal Gray - physiology | In Vitro Techniques | Neural Inhibition - drug effects | Inhibitory Postsynaptic Potentials - drug effects | Urea - pharmacology
Journal Article
American Journal of Physiology - Regulatory Integrative and Comparative Physiology, ISSN 0363-6119, 01/2013, Volume 304, Issue 1, pp. R23 - R32
The interaction between adenosine and soluble epoxide hydrolase (sEH) in vascular response is not known. Therefore, we hypothesized that lack of sEH in mice... 
Relaxation | CYP2J5-epoxgenase;ω-hydroxylase | receptor | Soluble epoxide hydrolase | Contraction | Adenosine A | Epoxide Hydrolases - physiology | Adenosine-5'-(N-ethylcarboxamide) - pharmacology | Butyrates - pharmacology | Male | Receptor, Adenosine A2A - physiology | Lauric Acids - pharmacology | Vasodilation - genetics | 8,11,14-Eicosatrienoic Acid - analogs & derivatives | Adenosine A2 Receptor Agonists - pharmacology | Urea - analogs & derivatives | Female | Benzamides - pharmacology | Oxygenases - physiology | Vasodilation - physiology | 8,11,14-Eicosatrienoic Acid - pharmacology | Adamantane - analogs & derivatives | NG-Nitroarginine Methyl Ester - pharmacology | Adamantane - pharmacology | Triazines - pharmacology | Phenethylamines - pharmacology | Vasodilator Agents - pharmacology | Enzyme Inhibitors - pharmacology | Gene Silencing | Adenosine - pharmacology | Pyrimidines - pharmacology | Epoxide Hydrolases - genetics | Triazoles - pharmacology | Adenosine A2 Receptor Antagonists - pharmacology | PPAR gamma - physiology | Animals | Adenosine - analogs & derivatives | Benzoates - pharmacology | Mice | Phenylurea Compounds - pharmacology | Pyridines - pharmacology | Vasodilation - drug effects | Urea - pharmacology | adenosine A2a receptor | CYP2J5-epoxgenase | ω-hydroxylase | relaxation | contraction | Cardiovascular and Renal Integration | soluble epoxide hydrolase | adenosine A1 receptor
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 08/2015, Volume 172, Issue 15, pp. 3805 - 3816
Journal Article
American Journal of Physiology - Heart and Circulatory Physiology, ISSN 0363-6135, 2015, Volume 308, Issue 9, pp. H1020 - H1029
This study addressed the hypothesis that inhibiting the soluble epoxide hydrolase (sEH)-mediated degradation of epoxy-fatty acids, notably epoxyeicosatrienoic... 
Insulin resistance | Cardiac function | Soluble epoxide hydrolase | Endothelium | endothelium | CARDIAC & CARDIOVASCULAR SYSTEMS | PHYSIOLOGY | HEART-FAILURE | RATS | MECHANISMS | soluble epoxide hydrolase | DIABETES-MELLITUS | CARDIOVASCULAR-DISEASE | PERIPHERAL VASCULAR DISEASE | cardiac function | DYSFUNCTION | HYPERTENSION | ARTERY | insulin resistance | EXPRESSION | Obesity - drug therapy | Coronary Vessels - physiopathology | Endothelium, Vascular - drug effects | Heart Diseases - prevention & control | Male | Endothelium, Vascular - enzymology | Obesity - blood | Dose-Response Relationship, Drug | Glyburide - pharmacology | Time Factors | Lipids - blood | Urea - analogs & derivatives | Inflammation Mediators - metabolism | Disease Models, Animal | Coronary Vessels - drug effects | Coronary Vessels - enzymology | Vasodilator Agents - pharmacology | Heart Diseases - physiopathology | Obesity - complications | Ventricular Function, Left - drug effects | Endothelium, Vascular - physiopathology | Enzyme Inhibitors - pharmacology | Insulin Resistance | Obesity - physiopathology | Heart Diseases - enzymology | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Heart Diseases - etiology | Animals | Eicosanoids - metabolism | Benzoates - pharmacology | Mice | Obesity - enzymology | Epoxide Hydrolases - metabolism | Vasodilation - drug effects | Blood Glucose - metabolism | Nitric Oxide - metabolism | Epoxide Hydrolases - antagonists & inhibitors | Ventricular Remodeling - drug effects | Urea - pharmacology | Prevention | Obesity | Enzymes | Physiological aspects | Hydrolases | Research | Heart diseases | Life Sciences | Call for Papers
Journal Article
Nature neuroscience, ISSN 1546-1726, 2013, Volume 16, Issue 8, pp. 1154 - 1161
Journal Article
Psychopharmacology (Berlin, Germany), ISSN 1432-2072, 2018, Volume 235, Issue 11, pp. 3083 - 3091
Sleep paralysis is a state of involuntary immobility occurring at sleep onset or offset, often accompanied by uncanny “ghost-like” hallucinations and extreme... 
Hypnopompic | Neurosciences | Hypnogogic | Hallucinogenic drugs | Biomedicine | Treatment | Sleep paralysis | Mystical experiences | Hallucinations | Serotonin 2A | Pharmacology/Toxicology | Psychiatry | Ketanserin | EGO-DISSOLUTION | PSYCHIATRY | EGYPTIAN COLLEGE-STUDENTS | HYPOCRETIN-OREXIN | NEUROSCIENCES | GENERAL-POPULATION | SPIRITUAL SIGNIFICANCE | SENSED PRESENCE | IN-VIVO | RECEPTOR ACTIVATION | PHARMACOLOGY & PHARMACY | DIRECT TREATMENT INTERVENTION | MYSTICAL-TYPE EXPERIENCES | Psilocybin - metabolism | Humans | Lysergic Acid Diethylamide - metabolism | Serotonin 5-HT2 Receptor Agonists - adverse effects | Serotonin 5-HT2 Receptor Agonists - pharmacology | Serotonin - pharmacology | Psilocybin - pharmacology | Piperidines - pharmacology | Urea - analogs & derivatives | Urea - metabolism | Sleep - physiology | Serotonin 5-HT2 Receptor Agonists - metabolism | Dopamine - metabolism | Sleep Paralysis - drug therapy | Hallucinations - drug therapy | Hallucinogens - pharmacology | Piperidines - metabolism | Dopamine - pharmacology | Hallucinations - chemically induced | Hallucinogens - metabolism | Hallucinations - metabolism | Neuropharmacology | Serotonin 5-HT2 Receptor Antagonists - pharmacology | Sleep - drug effects | Sleep Paralysis - chemically induced | Serotonin 5-HT2 Receptor Antagonists - metabolism | Serotonin 5-HT2 Receptor Antagonists - therapeutic use | Sleep Paralysis - metabolism | Urea - therapeutic use | Animals | Lysergic Acid Diethylamide - pharmacology | Piperidines - therapeutic use | Serotonin - metabolism | Lysergic Acid Diethylamide - adverse effects | Receptor, Serotonin, 5-HT2A - metabolism | Urea - pharmacology | Receptors | Hallucinations and illusions | Sleep | Serotonin | Research | Drug therapy | Health aspects | Drugs | Visual cortex | Dopamine | Lysergic acid diethylamide--LSD | Lysergic acid diethylamide | Visual pathways | Positron emission | Activation | Lysergide | Serotonin S2 receptors | Fear | Chromosome 13 | Anxiety | Paralysis | Psilocybine | Positron emission tomography | Dopamine receptors | Theoretical and Methodological
Journal Article
The Journal of neuroscience, ISSN 1529-2401, 2012, Volume 32, Issue 39, pp. 13597 - 13607
Endocannabinoid signaling has been shown to mediate synaptic plasticity by retrogradely inhibiting presynaptic transmitter release in several systems. We found... 
AVIAN MIDBRAIN | GABAERGIC TRANSMISSION | LONG-TERM PLASTICITY | SYNAPTIC-TRANSMISSION | CRITICAL PERIOD | CA2+ SENSOR | CB1 CANNABINOID RECEPTOR | CHICK SPINAL-CORD | HIPPOCAMPAL-NEURONS | PROTEIN-SYNTHESIS | NEUROSCIENCES | Endocannabinoids - metabolism | Analgesics - pharmacology | Spinal Cord - drug effects | Age Factors | Endocannabinoids - pharmacology | Endocannabinoids - agonists | Synaptic Potentials - drug effects | Neuronal Plasticity - drug effects | Male | Nerve Net - drug effects | Neuronal Plasticity - physiology | Piperidines - pharmacology | Heterocyclic Compounds, 1-Ring - pharmacology | Urea - analogs & derivatives | Female | Homeostasis - drug effects | Electric Stimulation - methods | Motor Neurons - drug effects | Pyrazoles - pharmacology | Synaptic Potentials - physiology | Motor Neurons - physiology | Morpholines - pharmacology | gamma-Aminobutyric Acid - pharmacology | Excitatory Amino Acid Agonists - pharmacology | Chick Embryo | Arachidonic Acids - pharmacology | Naphthalenes - pharmacology | Receptor, Cannabinoid, CB1 - metabolism | Spinal Cord - embryology | Patch-Clamp Techniques | Animals | Signal Transduction - drug effects | Homeostasis - physiology | Benzoxazines - pharmacology | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid - pharmacology | Endocannabinoids - antagonists & inhibitors | Urea - pharmacology
Journal Article
Cancer discovery, ISSN 2159-8290, 2012, Volume 2, Issue 6, pp. 524 - 539
Inhibition of the protein kinase WEE1 synergizes with chemotherapy in preclinical models and WEE1 inhibitors are being explored as potential cancer therapies.... 
DNA-DAMAGING AGENTS | MUTATION STATUS | ONCOLOGY | AGGRESSIVE BREAST-CANCER | GENOME INTEGRITY | CYCLIN B1 | CHROMOSOME CONDENSATION | INDUCED G CHECKPOINT | P53 MUTANT-CELLS | TUMOR-CELLS | KINASE INHIBITOR | Protein Kinases - metabolism | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Apoptosis - drug effects | Humans | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Thiazoles - therapeutic use | Quinolines - pharmacology | Tumor Suppressor Protein p53 - genetics | Breast Neoplasms - metabolism | Cell Cycle Proteins - antagonists & inhibitors | DNA-Binding Proteins - metabolism | Deoxycytidine - therapeutic use | Cyclins - metabolism | Urea - analogs & derivatives | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Pyrazoles - pharmacology | Cell Line | Pyrimidinones | Thiophenes - pharmacology | Pyrimidines - pharmacology | Mice, SCID | Breast Neoplasms - drug therapy | Enhancer of Zeste Homolog 2 Protein | Transcription Factors - metabolism | Xenograft Model Antitumor Assays | Polycomb Repressive Complex 2 | Urea - therapeutic use | Animals | Mitosis - drug effects | Tumor Burden - drug effects | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Checkpoint Kinase 1 | Mice | Protein Kinase Inhibitors - pharmacology | Quinolines - therapeutic use | S Phase - drug effects | Thiazoles - pharmacology | Deoxycytidine - analogs & derivatives | Urea - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Behavioural Pharmacology, ISSN 0955-8810, 10/2011, Volume 22, Issue 7, pp. 681 - 692
Parkinsonʼs disease psychosis (PDP) is a condition for which a safe, tolerated, and effective therapy is lacking. Treatment with typical or atypical... 
serotonin | substantia nigra | dopamine depletion | rat | Parkinson's disease psychosis | 6-hydroxydopamine lesion | animal model | RISK-FACTORS | D-1 | NEUROSCIENCES | RECEPTOR ANTAGONIST | SEROTONIN 5-HT2A | HALLUCINATIONS | NEURONS | BEHAVIORAL SCIENCES | PHARMACOLOGY & PHARMACY | HEAD-TWITCH BEHAVIOR | MPTP | STRIATUM | Antipsychotic Agents - toxicity | Central Nervous System Stimulants - pharmacology | Amphetamines - pharmacology | Hyperkinesis | Male | Parkinson Disease - drug therapy | Motor Activity | Serotonin Receptor Agonists - pharmacology | Behavior, Animal | Fluorobenzenes - pharmacology | Psychotic Disorders - physiopathology | Piperidines - pharmacology | Antipsychotic Agents - therapeutic use | Urea - toxicity | Urea - analogs & derivatives | Disease Models, Animal | Parkinson Disease - complications | Piperidines - toxicity | Amphetamine - pharmacology | Tyrosine 3-Monooxygenase - analysis | Serotonin 5-HT2 Receptor Antagonists - pharmacology | Fenfluramine - pharmacology | Rats, Sprague-Dawley | Sensory Gating | Dyskinesias - metabolism | Oxidopamine - toxicity | Receptor, Serotonin, 5-HT2A - physiology | Urea - therapeutic use | Animals | Serotonin Agents - pharmacology | Serotonin 5-HT2 Receptor Antagonists - toxicity | Piperidines - therapeutic use | Psychotic Disorders - drug therapy | Antipsychotic Agents - pharmacology | Substantia Nigra - physiology | Urea - pharmacology | Parkinson Disease - etiology
Journal Article
BMC Cancer, ISSN 1471-2407, 08/2014, Volume 14, Issue 1, pp. 570 - 570
Journal Article
Journal Article
Neuropsychopharmacology (New York, N.Y.), ISSN 1740-634X, 2017, Volume 43, Issue 5, pp. 1001 - 1009